Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)

BACKGROUND: There is no consensual treatment of locally advanced or metastatic chordomas. PATIENTS AND METHODS: We conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib (800 mg/day). The primary end point was the 9-month progression-free rate according to RECIST 1.1. All pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J. Y., Amela, E. Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576908/
https://www.ncbi.nlm.nih.gov/pubmed/26202596
http://dx.doi.org/10.1093/annonc/mdv300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576908/
https://www.ncbi.nlm.nih.gov/pubmed/26202596
http://dx.doi.org/10.1093/annonc/mdv300

Ejemplares similares